Lv3
368 积分 2024-01-26 加入
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
14小时前
已完结
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
1天前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
1天前
已完结
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
1天前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1天前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
16天前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
24天前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
1个月前
已完结
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
1个月前
已完结
Prospects of neutrophilic implications against pathobiology of chronic obstructive pulmonary disease: Pharmacological insights and technological advances
1个月前
已完结
皖公网安备34019202002308
